MX2019014226A - Novel solid phases of dapagliflozin. - Google Patents

Novel solid phases of dapagliflozin.

Info

Publication number
MX2019014226A
MX2019014226A MX2019014226A MX2019014226A MX2019014226A MX 2019014226 A MX2019014226 A MX 2019014226A MX 2019014226 A MX2019014226 A MX 2019014226A MX 2019014226 A MX2019014226 A MX 2019014226A MX 2019014226 A MX2019014226 A MX 2019014226A
Authority
MX
Mexico
Prior art keywords
dapagliflozin
solid phases
novel solid
relates
derivative
Prior art date
Application number
MX2019014226A
Other languages
Spanish (es)
Inventor
Arroyo Héctor Senosiain
Vásquez Karina Mondragón
CHÁVEZ Jorge Guillermo DOMINGUEZ
Original Assignee
Alparis Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alparis Sa De Cv filed Critical Alparis Sa De Cv
Priority to MX2019014226A priority Critical patent/MX2019014226A/en
Priority to PCT/IB2020/058180 priority patent/WO2021105779A1/en
Priority to DO2022000112A priority patent/DOP2022000112A/en
Publication of MX2019014226A publication Critical patent/MX2019014226A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to solid compounds, referred to as novel solid phases (NFS) of Dapagliflozin (DPG) co-crystals and coamorphs, selected from a) a carboxylic acid derivative that has an amino group in the alpha position or b) a hydroxybenzene derivative, c) a dihydroxybenzoic acid, and d) an aliphatic dicarboxylic acid. Also, it relates to the respective solvates, hydrates, and polymorphs thereof for preparing a composition for controlling and preventing hyperglycemia in diabetic patients.
MX2019014226A 2019-11-27 2019-11-27 Novel solid phases of dapagliflozin. MX2019014226A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2019014226A MX2019014226A (en) 2019-11-27 2019-11-27 Novel solid phases of dapagliflozin.
PCT/IB2020/058180 WO2021105779A1 (en) 2019-11-27 2020-09-02 New solid forms of dapagliflozin
DO2022000112A DOP2022000112A (en) 2019-11-27 2022-05-26 NEW SOLID PHASES OF DAPAGLIFLOZIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019014226A MX2019014226A (en) 2019-11-27 2019-11-27 Novel solid phases of dapagliflozin.

Publications (1)

Publication Number Publication Date
MX2019014226A true MX2019014226A (en) 2022-09-23

Family

ID=76129202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014226A MX2019014226A (en) 2019-11-27 2019-11-27 Novel solid phases of dapagliflozin.

Country Status (3)

Country Link
DO (1) DOP2022000112A (en)
MX (1) MX2019014226A (en)
WO (1) WO2021105779A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR20160016025A (en) * 2014-08-01 2016-02-15 한미정밀화학주식회사 Novel hydrate complex of dapagliflozin and method for preparing same
CN105524033A (en) * 2014-09-28 2016-04-27 上海阳帆医药科技有限公司 Fumaric acid eutectic of dapagliflozin, and preparation method and pharmaceutical composition thereof
WO2017191539A1 (en) * 2016-05-02 2017-11-09 Aurobindo Pharma Limited Process for the preparation dl-proline co-crystal of dapagliflozin
KR102111247B1 (en) * 2019-08-16 2020-05-14 유니셀랩 주식회사 Amorphous state of New dapagliflozin cocrystal or complex

Also Published As

Publication number Publication date
WO2021105779A1 (en) 2021-06-03
DOP2022000112A (en) 2022-07-15

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
JP6294868B2 (en) Liquid aqueous composition
MX2009010965A (en) Tem8 peptides and vaccines comprising the same.
MX2020001525A (en) Glp-1 compositions and uses thereof.
PH12018502465A1 (en) Mic-1 compounds and use thereof
MX2020009000A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists.
MX2020008265A (en) Pharmaceutical 6,5 heterobicyclic ring derivatives.
WO2018097603A3 (en) Middle east respiratory syndrome coronavirus s protein immunogenic composition and method for preparing same
MX2018013519A (en) Enhancer of zeste homolog 2 inhibitors.
MX2019009964A (en) Novel clostridium perfringens bacteriophage clo-pep-2 and use for inhibiting clostridium perfringens proliferation of same.
MX2019005775A (en) Pharmaceutical parenteral formulation containing carglumic acid.
BR112016027526A2 (en) proline-specific endoprotease and its use
MX355759B (en) Topk peptides and vaccines including the same.
MY182914A (en) Pyridinium compounds
MX2019014226A (en) Novel solid phases of dapagliflozin.
WO2016139683A3 (en) Pharmaceutical compositions of lurasidone and process for preparing the same
WO2018143666A3 (en) Polypeptide derived from cap1 and pharmaceutical composition comprising same as effective ingredient
PH12020551368A1 (en) Composition for enhancing cognitive function, composition for remedying anxiety symptoms, and composition for suppressing cerebral atrophy
CA2819463C (en) Tomm34 peptides and vaccines including the same
MX2021006259A (en) Oxyntomodulin peptide analog formulations.
MX2011008917A (en) Vangl1 peptides and vaccines including the same.
MX2017013480A (en) Pharmaceutical composition for treating and/or preventing cancer.
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
MX2020010422A (en) Variant maltogenic alpha-amylase.